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ABSTRACT 
Acute antibody-mediated rejection (AMR) occurs in a small minority of sensitized 
liver transplant recipients. Although histopathologic characteristics have been 
described, specific features that could be used: a) for a generalizable scoring system; 
and b) to trigger a more in-depth analysis are needed to screen for this rare but 
important finding. Toward this goal, we created a training and validation cohort from 3 
high volume liver transplant programs of putative acute AMR and control cases that 
were evaluated blindly by 4 independent transplant pathologists.  Evaluations were 
performed on H&E sections alone without knowledge of either serum DSA results or 
C4d stains. Routine histopathological features strongly correlated with severe acute 
AMR included portal eosinophilia, portal vein endothelial cell hypertrophy, eosinophilic 
central venulitis, central venulitis severity, and cholestasis.  Acute AMR inversely 
correlated with lymphocytic venulitis and lymphocytic portal inflammation. These and 
other characteristics were incorporated into models created from the training cohort 
alone. The final Acute-AMR (aAMR) score (portal vein endothelial cell hypertrophy + 
portal eosinophilia + eosinophilic venulitis / lymphocytic portal inflammation + 
lymphocytic venulitis) exhibited a strong correlation with severe acute AMR in the 
training (OR=2.86, p<0.001) and validation cohort (OR=2.49, p<0.001). SPSS tree 
classification was used to select 2 cutoffs, one that optimized specificity at a score 
>1.75 (sensitivity = 34%, specificity = 87%) and a second that optimized sensitivity at a 
score >1.0 (sensitivity = 81%, specificity = 71%). In conclusion, routine histopathological 
features of aAMR score can be used to screen for acute AMR on routine H&E in 
indication liver transplant biopsies, however, a definitive diagnosis requires 
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substantiation by donor-specific HLA alloantibody testing, diffuse C4d staining, and 
exclusion of other insults.  
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INTRODUCTION 
The first evidence that antibodies can cause acute injury/rejection (antibody-
mediated rejection; AMR) in human liver allografts was observed in ABO-incompatible 
cadaveric, brain-dead whole organ donors (1, 2).  Antibody and complement deposition, 
platelet-fibrin thrombi, micro-vasculitis, and arteritis were typical and expected 
histopathological findings (1), based on previous observations in ABO-incompatible 
renal allografts (3) and in ABO-compatible renal allografts harboring alloantibodies (4, 
5). 
It was recognized early on, however, that human liver allografts were highly 
resistant to acute AMR from preformed HLA alloantibodies compared to kidney 
allografts (6).  This relative resistance was attributed to: the liver’s inherent “tolerogenic” 
properties, the difficultly detecting antibody and complement tissue deposits, the paucity 
of typical histopathological findings (6) and, even when damage was present, to the 
noticeably diminished severity of injury compared to ABO-incompatible liver transplants 
(7, 8).  Relative hepatic resistance to AMR has been attributed to: a) secretion of 
soluble HLA class I molecules that form immune complexes with alloantibodies, which 
are then cleared by Kupffer’s cells; b) Kupffer cell phagocytosis of platelet aggregates, 
immune complexes, and activated complement components (9); c) limited distribution of 
HLA class II expression in the microvasculature; d) large liver size and dual hepatic 
vasculature; and e) marked hepatocyte regenerative capacity after injury [reviewed in 
(7, 8)].  In addition, the inferior sensitivity and specificity of cell-based cytotoxic antibody 
detection methods impaired prior investigators abilities to find associations between 
HLA antibodies and adverse patient and graft outcomes (1, 7, 8).    
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Nevertheless, in the late 1980’s and early to mid-1990’s HLA class I and II 
antibodies, as measured in cytotoxic cell-based assays, were suspected to cause or 
substantially contribute to acute and chronic liver allograft rejection (7, 10-13).  In 
addition, experimental rat studies clearly showed that extreme sensitization (14, 15) 
could override the liver’s natural resistance and defense mechanisms.  Similar 
observations were made in humans and risk factors for acute liver allograft AMR 
included high-titer pretransplant sensitization with persistence of serum alloantibodies 
after transplantation. When acute liver allograft AMR ensued, refractory 
thrombocytopenia, circulating immune complexes, and severe liver injury were then 
seen (7, 11).  
Recent studies using more sophisticated and sensitive (16) solid phase donor-
specific HLA alloantibody (DSA) detection methods have confirmed and extended 
earlier studies with cytotoxic cell-based assays, even though the two tests have been 
documented to sometimes produce substantially different results on the same serum 
samples (17).  These confirmed findings include: 1) the liver allograft’s relative 
resistance to AMR (18, 19) associated with the rapid disappearance of the vast majority 
of low to moderate MFI class I and II alloantibodies (11, 17, 18); and 2) an association 
of acute AMR with high-titer alloantibodies that most-often persist after transplantation 
and result in refractory thrombocytopenia and acute liver injury that can evolve into 
combined acute antibody-mediated and T-cell-mediated rejection.  Inadequately treated, 
the end result can be chronic or ductopenic rejection (17, 20-24).  Solid phase DSA 
analyses have also shown an association between multiple IgG subclasses, especially 
when alloantibodies of the IgG3 subclass are present, and chronic rejection and 
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diminished allograft survival (25).  These newer serum assays have also facilitated a 
closer correlation between histopathological findings and serum DSA characteristics 
(18, 23, 24, 26).   
Histopathological patterns of injury associated with acute liver allograft AMR 
include organ-specific findings such as portal edema, ductular reaction, eosinophilia, 
hepatocyte swelling and hepatocanalicular cholestasis, and histopathological findings 
similar to those seen with acute AMR in other solid organ allografts such as marked 
(portal) microvascular endothelial cell hypertrophy and monocytic/histiocytic, 
eosinophilic, and neutrophilic (portal) microvasculitis.  During the early stages, the 
constellation of findings can resemble preservation/reperfusion injury or biliary 
stricturing, but often quickly progress to acute “cellular” or T-cell-mediated and finally 
chronic rejection (8, 11, 22-24, 26, 27).  Detection of microvascular complement 
deposition with C4d staining has been a valuable adjunct to the histopathological 
evaluation for acute AMR in all solid organ allografts, but C4d staining should not be 
used in isolation to establish an AMR diagnosis in liver allografts [reviewed in (27-29)].   
Finally, although severe acute AMR is rare, unrecognized it can lead to allograft 
failure (23, 30, 31), as evidenced by its substantial contribution to ~ 10-20% of 
previously idiopathic early allograft failures (<90 days post-transplant) in sensitized 
patients (24).  Early recognition of acute AMR can prompt plasmapheresis (32) and 
plasma cell-specific therapy in rare patients and may result in improved outcomes (23, 
30).  Toward the goal of facilitating earlier diagnosis of severe acute liver allograft AMR, 
this study was designed to identify and validate a limited constellation of routine 
histopathological features in the form of a generalizable scoring system on liver biopsy 
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H&E analysis that can be easily used to trigger a more thorough clinicopathological 
evaluation (serum DSA testing, tissue C4d staining, and exclusion of other causes of a 
similar type of injury) needed to establish the diagnosis with certainty.   
 
MATERIALS AND METHODS 
Case Selection & Study Design: 
Previous University of Pittsburgh Medical Center (UPMC) studies examined the 
effect of a conventional lymphocytotoxic crossmatch on patient and allograft survival (7) 
and the utility of C4d staining in primary liver allograft recipients (27). As part of these 
prior studies a constellation of severe histopathological findings associated with acute 
AMR was described (27).  These findings included microvascular (portal vein and portal 
capillary) endothelial cell hypertrophy; variable histiocytic, eosinophilic, and neutrophilic 
portal inflammation with microvasculitis; portal/periportal edema; cholangiolitis; 
centrilobular hepatocyte swelling; and hepatocanalicular cholestasis. AMR-related 
microvasculitis was defined as inflammatory cells adherent to, or near, the luminal 
aspect of hypertrophied endothelial cells, which differs from the subendothelial 
lymphocytic infiltration of portal and central veins seen in typical T-cell-mediated 
rejection. The goals of this study were: 1) to determine whether four pathologists from 3 
different liver transplant centers in two continents could blindly recognize 
histopathological findings of severe AMR on H&E staining alone associated with 
diffusely C4d-positive putative AMR episodes, and 2) to develop and validate a simple, 
generalizable scoring system that would facilitate recognition and an earlier diagnosis of 
acute AMR in liver allografts.    Cases of acute AMR were selected based on the 
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following criteria (24): 1) microvascultitis (as described above), 2) diffusely positive C4d-
staining (>50% of portal tracks with positive C4d staining of the portal microvasculature 
with or without sinusoidal or central vein staining) , 3) elimination of other causes of a 
similar type of injury, and 4) DSA in serum.  However, because of a lack of serum 
available for re-testing and the known insensitivity of cell-based cytotoxic assays, DSA 
was not required in the training cohort.  
The training set consisted of UPMC for cause biopsies (n = 26) obtained within 
21 days of primary liver transplant and divided into two groups: 1) those showing 
evidence of putative acute AMR with or without co-existent “cellular” rejection (n=13); 
and 2) an equally-sized group of control biopsies matched for Banff rejection grade 
severity (n = 13; indeterminate = 4; mild = 6; moderate = 3), but with negative C4d 
staining.   
A single blinded pathologist (AJD) re-reviewed the H&E-stained slides without 
knowledge of the C4d results and evaluated 27 different histologic features. After the 
initial appraisal, several histopathological categories were combined and those with a p-
value <0.3 or those with a strong pathophysiological basis for inclusion remained part of 
the final list of 9 variables (Table 3).  Following selection of the histopathological 
variables, 3 additional pathologists (SMS, CB, and MAN) evaluated the training material 
without knowledge of the number of C4d-positive or C4d-negative cases in each group 
that originated outside their own institution or C4d staining results for all cases. 
Variables positively associated with putative AMR or mixed AMR and T-cell-mediated 
rejection in the training set were considered for inclusion in the numerator of the model 
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based on a p-value <0.2. The denominator variables were selected for their negative 
association with AMR.  
Multiple models were made from the training cohort variables based on the 
following guiding principles: 1) a scientific understanding of AMR, 2) simplicity, 3) the 
least inter-observer variability, and 4) the best correlation with C4d staining.  The final 
model was selected for its lowest p-value from the training cohort data only.  
Following evaluation of the UPMC training set, a separate validation cohort was 
created from 2 different centers: 1) Edinburgh University and 2) Baylor University 
Medical Center (BUMC). The Edinburgh University cases (between 2007 and 2013) 
were selected in a similar fashion to UPMC cases: a diagnosis of rejection within 21 
days of transplant with histopathological evidence of rejection-related injury, strong and 
diffuse microvascular C4d staining, and fortunately a pretransplant positive cytotoxic or 
flow crossmatch or single antigen bead assay was available for all cases (n=5) and 
matched to a control group based on the Banff grade of cellular rejection with negative 
C4d staining and negative pre-transplant DSA testing (n=5).   
The second portion of the validation cohort included all 29 HCV RNA-negative 
cases of biopsy-proven steroid-resistant rejection from BUMC within 60 days of liver 
transplantation with single antigen bead testing performed pre-transplant (from 1/1/00 to 
5/31/09) (21).  This approach was based on the unrealized expectation that the cohort 
would be enriched for recipients suffering from acute AMR (22), but only 4 stained 
diffusely positive for C4d and 1 showed focal positivity.  C4d staining was performed at 
UPMC using the listed protocol.  Three showing diffuse C4d positivity were also DSA 
positive and included in the final group; the remaining two cases: one originally 
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interpreted as diffuse had high background staining and one with focal C4d positivity 
were excluded because of equivocal C4d staining and negative DSA testing leaving a 
total of 27 cases. None of the DSA-negative cases had definitive diffuse C4d-positive 
staining. 
To achieve adequate statistical power we combined the Edinburgh and BUMC 
cohorts into one validation cohort.  The appraisal performed by all pathologists on this 
validation cohort was on the H&E material alone without knowledge of the C4d staining 
results. All biopsies were obtained before therapy for rejection was initiated.  
 
C4d Staining Protocol 
Deparaffinized and hydrated slides were treated with Target Retrieval Solution, 
pH=9.0 (DAKO, Carpinteria, CA) in a pressure cooker for 10 min to unmask antigens. 
After blocking slides, rabbit polyclonal anti-human C4d antibody [1:30-1:50, distributed 
by Alpco Diagnostics, Salem, NH in the United States and Biomedica, Austria in Europe 
(BI-RC4d)] was applied and incubated at 4°C overnight. After washing with PBS 3 
times, biotinylated goat anti-rabbit antibody, VECTASTAIN Elite ABC kit (Vector 
Laboratory, Burlingame, CA) with: AEC Chromogen (Scytek Laboratories, Logan, 
UT), DAB Chromogen (Vector Laboratory) or Bond ™ Polymer Refine Red Detection 
(Leica Biosystems, Buffalo Grove, IL) and Vector Red Alkaline Phosphatase Substate 
kit (Vector Laboratory) was used for visualizing C4d staining and counterstained with 
hematoxylin for visualization. 
 
Pretransplant DSA Evaluation 
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All UPMC patients had a pretransplant T-cell cytotoxic crossmatch preformed 
prior to liver transplantation. In crossmatch-positive patients a steroid recycle was 
routinely given regardless of laboratory parameters, followed by standard per protocol 
immunosuppression. Neither pretransplant nor post-transplant serum was available for 
single antigen bead DSA analysis.  
All Edinburgh University patients had pretransplant DSA testing performed since 
2007; however the protocol has evolved: from 2007 to 2010 a cytotoxic T- and B-cell 
crossmatch, from 2011 to 6/2012 a flow cytometric crossmatch, and since 7/2012 all 
patients are screened for anti-HLA antibodies with multi-antigen beads to class I and 
class II antigens, with single antigen bead testing for DSA specificities in all positive 
patients.  
All BUMC patients had prospectively collected pretransplant serum available for 
retrospective analysis of preformed DSA by single antigen bead technology, where 
mean fluorescence intensity (MFI) ≥5000 was considered positive, although data was 
acquired and reported on all DSA with MFI ≥1000. All patients and donors were typed 
for HLA-A, -B, -DRB1, -DRB345 and -DQ using commercially available serologic typing 
trays or by molecular methods (Terasaki HLA tissue typing trays and Micro SSPTM or 
LabType® SSO, respectively; One Lambda Inc., Canoga Park, CA). All sera were 
blindly analyzed at the Terasaki Foundation Laboratory for HLA IgG antibodies using 
LABScreen single antigen class I (lot 6) and II (lot 8) beads (One Lambda Inc., Canoga 
Park, CA) according to the manufacturer's protocol. No serum was available to perform 
additional testing at the time of liver biopsy for any cohort. 
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Statistical Analyses 
Patient characteristics for the 3 cohorts are reported with median values and 
interquartile ranges of continuous data and percentages of categorical data where 
appropriate. Chi squared analyses of categorical variables and two-sample t-tests of 
continuous variables were performed. Univariate logistic regression was utilized to 
evaluate individual variables and the model’s ability to predict association with C4d 
positive rejection. 
Although our final model produced a linear score, the output was not thought to 
be linearly associated with the ability to predict AMR. Therefore, we employed SPSS 
16.0 to determine predictive cutoffs using tree classification. This was performed on the 
training cohort data from all 4 blinded pathologists before the validation cohort data was 
available for analysis and not modified after its completion.  
Inter-observer variability was assessed with the Kendall’s coefficient of 
concordance (33). Coefficient of concordance analyses were performed for each 
individual variable. This measure, unlike the Kappa statistic, is for ordinal values and 
takes into consideration the magnitude of disagreement between evaluators. For the 
final model the coefficient of concordance measured their agreement on the Acute-AMR 
(aAMR) category (≤1, >1 but ≤1.75 and >1.75).  
Significance was always defined as a P<0.05. SAS 9.1 was used for all statistical 
analyses except SPSS 16.0 was utilized for tree classification. 
 
RESULTS 
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Patient characteristics for the 3 cohorts are presented in Table 1. The cohorts 
were chosen differently because of local care standards, therefore, intergroup 
differences existed, but because of the blinded nature of analysis, none were felt to 
substantially influence the results.  
Table 2A shows pretransplant T-cell cytotoxic crossmatch data from UPMC 
cases according to C4d staining; of the 13 diffusely C4d positive cases 38% were T-cell 
crossmatch positive, whereas the remainder was T-cell crossmatch negative.  All C4d-
negative cases/biopsies had a negative T-cell cytotoxic crossmatch except one. Table 
2B shows the pretransplant DSA correlation with C4d staining in the Edinburgh cases.  
All C4d positive cases had evidence of pre-transplant DSA by either single antigen 
beads [class I MFISUM of 28,500 and class II MFISUM of 27,300] (n=1), T-cell flow 
crossmatch (n=1), or T-cell cytotoxic crossmatch (n=3).  All C4d negative controls were 
also DSA negative by either single antigen bead analyses (n=4) or flow crossmatch 
(n=1).  Table 2C shows the pretransplant single antigen bead data from the BUMC 
cases:  only 3 cases were C4d positive with DSA in serum, and each one had at least 
one DSA with MFI ≥5000.  The first had a single class I DSA with MFI of 11,353, the 
second had 2 class I DSAs with MFISUM of 13,620 and 4 low MFI (all between 1000 and 
4999) class II DSAs with MFISUM of 9,066, and the third had one class I DSA with MFI 
1,868 and 5 class II DSAs with MFISUM of 62,375. None of the C4d negative cases had 
any single DSA with a MFI ≥5000, but nine had low MFI DSAs (between 1000 and 
4999); 2 with class I only, 4 with class II only and 3 with class I and II.  
Table 3 highlights the 7 evaluated histologic characteristics associated with C4d 
positive early rejection or putative acute AMR (Figures 1-4): eosinophilic central 
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venulitis, portal vein endothelial cell hypertrophy, eosinophilic portal venulitis, central 
venulitis severity, portal eosinophilia, hepatocyte ballooning, and cholestasis; and 2 
histologic characteristics inversely associated with acute AMR in the training cohort: 
lymphocytic portal inflammation and lymphocytic venulitis (Figure 2). Although 
cholestasis was not associated with DSA injury when all 4 pathologists scores were 
utilized in the training cohort, when particular attention was refocused to distinguish 
hepatocanalicular cholestasis from centrilobular hepatocyte lipofuscin deposition, an 
association was found in the validation cohort. In addition, the coefficients of 
concordance improved significantly after learning from the training cohort was followed 
by evaluation of the validation cohort.  
Next, multiple models were created from the training cohort data alone, but 
Figure 5 shows the final Acute-AMR (aAMR) score. Numerical values are assigned 
based on the percentage of structures affected (None = 0, <10% = 1, 10-50% = 2, and 
>50% = 3). For the final model chosen, the OR was not appreciably changed from the 
training (OR=2.86, P<0.001) to the validation cohort (OR=2.49, P<0.001).  
Next tree classification was utilized on the training cohort to optimize the 
specificity for one cutoff and sensitivity for the other cutoff of the aAMR score (Figure 5). 
Sensitivity in the validation cohort increased from 34% to 81% when the cutoff used 
decreased from >1.75 to >1 respectively. Specificity in the validation cohort also 
decreased from 87% and 71% when the cutoff used decreased from >1.75 and >1 
respectively. In addition, the Kendall’s coefficient of concordance between pathologists 
was 0.61 in the training and 0.50 in the validation cohorts. 
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DISCUSSION 
Consensus histopathological criteria exist for the diagnosis of acute AMR in all 
solid organ transplants with the notable exception of the liver (5, 34-39), mostly because 
of its relative resistance to AMR and, consequent rarity of recognized cases.  Absolute 
criteria for AMR in extra-hepatic organs invariably include serum DSA, microvascular 
endothelial cell hypertrophy and micro-vasculitis (40, 41), other tissue-specific injury 
patterns, and usually diffuse microvascular C4d staining. Kidney and heart allografts 
(41), however, allow for C4d-negative AMR when convincing microvasculitis is identified 
in the presence of DSA in serum.  
Consensus criteria development for acute liver allograft AMR has been 
hampered by several issues, which, in turn, are related to the well-documented relative 
hepatic resistance to acute AMR: 1) in contrast to other solid organs, only a small 
fraction of DSA-positive liver allograft recipients develop overt histopathological 
evidence of injury (11, 17, 18, 24, 42); consequently 2) few programs routinely tissue 
type and screen for alloantibodies, or stain for C4d, mostly because they do not find it 
“cost effective”; and therefore, 3) only a few robust studies correlate histopathological 
findings, solid phase DSA testing, and C4d staining (18, 23, 24), and even fewer tissue 
biopsy and serum samples are simultaneously obtained.  
Nevertheless, recent liver allograft studies confirmed and extended earlier 
observations by showing that high-titer DSA, in the presence of refractory 
thrombocytopenia, and diffuse microvascular C4d staining increase the probability of 
acute AMR (8, 23, 24, 43).  The ability to correlate DSA with impaired outcomes, 
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however, remains suboptimal (17, 20, 21, 44) and more granular and specific 
histopathological criteria are needed. 
Diffuse C4d positivity remains a critical component of an acute liver allograft 
AMR diagnosis at this time.  However, C4d staining should not be interpreted in 
isolation (23, 24, 26, 27, 30) because C4d staining protocols for formalin-fixed, paraffin-
embedded liver allograft tissue are evolving toward more sensitive techniques.  In 
addition, correlation of staining results with liver dysfunction need improvement because 
even diffuse microvascular endothelial cell C4d deposits can occur with or without 
histopathological or serological evidence of liver injury [reviewed in (27-29, 45)].  Liver 
resistance mechanisms (listed above); more restricted hepatic microvasculature class II 
HLA expression compared to other organs; or the liver’s position downstream from the 
intestine and complement activation by the lectin pathway, by bacterial products, and 
other factors all contribute to the complexities involved.  Even so, most studies show a 
correlation between cell-based and often a stronger correlation with solid-phase 
evidence of DSA and tissue C4d staining [reviewed in (27-29, 45)].  A key 
consideration, therefore, is how to reliably recognize acute microvascular and perhaps 
stellate cell activation and injury from DSA in liver allografts? 
In our opinion, the strong correlation between several histopathological features 
of microvascular activation (endothelial cell hypertrophy) and injury (microvasculitis) 
documented in a blinded analysis by 4 independent pathologists, as would be expected 
with AMR, and diffuse C4d staining and serum DSA in the validation cohort provide 
compelling evidence that antibodies substantially contribute to this injury pattern.  The 
argument is further substantiated by the relative paucity of similar correlations in more 
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typical lymphocyte-predominant acute T-cell-mediated rejection biopsies matched for 
Banff grade of severity in controls.   
It should be noted, however, that AMR-related microvasculitis is recognized 
primarily by increased intra-luminal inflammatory cells, some of which might be 
adherent to or apparently embedded within endothelial cells, and differs from the 
subendothelial lymphocytic infiltration of portal and central veins seen in otherwise 
typical T-cell-mediated rejection.  Interestingly, some features originally attributed to T-
cell-mediated rejection, such as an emphasis on a “mixed” inflammatory infiltrate 
consisting of activated and smaller lymphocytes, macrophages, neutrophils, and 
especially eosinophils (46), likely lumped together mixed T-cell-mediated and antibody-
mediated effector mechanisms because of a lack of adequate tools to differentiate the 
two.  Combined AMR and T-cell-mediated rejection is typical of many rejection episodes 
in all solid organ allografts.  Therefore, changes attributable to AMR-related injury might 
be more difficult to isolate in livers simply because of convention.   
Screening for acute AMR can be easily accomplished by using parameters 
included in the aAMR score on indication liver biopsies. We recommend using features 
identified in the overall score to screen for putative cases.  Eosinophilia had the 
strongest correlation with acute AMR of any single histologic characteristic (HR = 4.37, 
p<0.001)However, using the aAMR score in clinical practice, or specifically examining 
cases for AMR-associated features, should facilitate identification of the most severe 
cases of AMR.  We opted, therefore, for high specificity and set a relatively high 
threshold aAMR score of >1.75 to raise significant concern for an acute AMR diagnosis.  
This approach is recommended because of potential consequences of AMR therapy 
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and to avoid over-diagnosis, which would inhibit widespread acceptance of a diagnosis 
that many already view with skepticism.  Eventually, however, to improve sensitivity 
biopsies with scores >1 should be subjected to C4d staining and serum DSA testing 
should be carried out to substantiate or refute a putative AMR diagnosis. This will 
enable recognition of the entire spectrum of changes associated with AMR. 
This study evaluated acute AMR at a more granular level than prior appraisals in 
an effort to help recognition of the most severe form of acute AMR.  However, there are 
several shortcomings. One, training and validation cohorts were selected differently 
because of local standards of care. Two, there are no current Banff criteria for acute 
AMR, and therefore previous descriptions were used to select cases (27). Three, in the 
training cohort not all recipients with diffuse C4d-positive putative AMR showed pre-
sensitization based on conventional T-cell cytotoxic crossmatches, which: a) miss most 
class II DSA; and b) are less sensitive (16) and can show substantially different results 
than solid phase assays when testing the same serum (17). The validity of this training 
cohort selection is substantiated by our BUMC patients in the validation cohort where a 
strong correlation between MFI of DSA and C4d staining was found: all patients with 
steroid resistant rejection and at least one DSA with MFI ≥5000 stained C4d positive, 
and all patients with steroid resistant rejection with lower MFI (1000 – 4999) DSA were 
C4d negative. Four, unavailability of simultaneous serum DSA testing and liver biopsy 
tissue hindered our ability to make tighter correlations. Five, part of our validation cohort 
was chosen from all the early (<60 days) steroid-resistant rejections that occurred in 
HCV RNA negative patients with pre-transplant DSA testing; this was done based on 
prior data showing this approach would enrich (41%) for C4d positive rejection (22), 
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however, only 11% of this group had C4d positive steroid resistant rejection.  Finally, 
the histopathological changes shown in this manuscript represent only the most severe 
form of acute liver allograft AMR.  
We attempted to mitigate most of these shortcoming by selecting cases from 3 
different institutions, evaluating all material without knowledge of C4d or DSA test 
results, including 4 different pathologists, creating training and validation cohorts (the 
latter having solid phase DSA testing for most cases) and, relying on stringent criteria, 
including:  1) histopathological evidence of diffuse microvascular activation, injury, and 
microvasculitis; 2) diffuse microvascular C4d staining; 3) serum DSA (usually high MFI); 
and 4) reasonable exclusion of other causes of a similar type of injury (24).  However, 
over time our understanding of acute AMR and C4d staining protocols will improve and 
molecular signatures of liver allograft AMR will be developed. As these advances unfold 
we expect that, like renal transplant pathology, histopathological features of acute and 
chronic liver AMR will be even more precisely defined, and C4d negative AMR will be 
described.  
In summary, routine histopathological features in the aAMR score can be used to 
suspect the most severe form of acute AMR, a diagnosis that requires further 
substantiation by donor-specific HLA alloantibody testing, C4d staining, and exclusion of 
other insults. In the future, more subtle forms of DSA induced liver allograft injury will 
likely be discovered and described.  
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Figure Legends.   
 
Figure 1.  Composite of early acute AMR histopathological changes in an allograft that 
failed 18 days after transplantation because of hepatic artery thrombosis in a highly 
sensitized patient.  A) Note the monocytic and eosinophilic “capillaritis” in the peribiliary 
capillary plexus (arrows) surrounding a large segmental bile duct (BD) on H&E stain 
(40X).  B) A C4d stain of the same area and throughout the entire liver showed diffuse 
endothelial cell C4d positivity (red *; 40X).   C) Monocytic capillaritis was also noted in 
the smaller portal tracts (PT; 30X) (arrow shows area shown at higher magnification in 
the inset (80X).  D) A C4d stain (red) showed strong and diffuse portal microvascular 
positivity, typical of severe acute AMR. 
 
Figure 2.  Composite histopathological features of severe, acute, C4d+ antibody 
mediated rejection (AMR) (A-F).  A) Note intense and diffuse C4d staining (red) in the 
portal vein (PV) and portal capillaries (*).  B)  Routine H&E appearance of the same 
portal tract as shown in A).  C) Shows a C4d stain (red) of the same portal vein (PV) 
branch as B) at higher magnification. D) Shows the routine H&E appearance of this 
vein.  Note the marked portal venous endothelial cell hypertrophy of a tangentially 
sampled vein with eosinophils and histiocytes embedded within the hypertrophied 
endothelial cells.  E)  Another C4d staining example of the portal venous changes 
typical of severe acute AMR with the H&E counterpart shown in figure F).  A scale bar is 
shown at the top left of each image. 
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Figure 3. High magnification (60X) H&E stain of the marked microvascular endothelial 
cell hypertrophy and cytoplasmic eosinophilia (arrows) that is typical of severe acute 
AMR.  Note the cuboidal or “hobnail” appearance of the endothelial cells. 
 
Figure 4.  Inflammatory arteritis was present in several of the cases diagnosed as 
severe acute AMR, as in other solid organ allografts (H&E; 20X).  This biopsy was 
obtained 11 days after transplantation from a 66-year-old female who underwent liver 
transplantation for primary biliary cirrhosis and hepatocellular carcinoma.  Solid phase 
DSA determination revealed several class 1 and 2 DSA at a cumulative MFI >50,000. 
When arteritis is detected, C4d staining (inset) and DSA determinations are 
recommended.  Arteritis, however, was not included in the acute AMR score because it 
is uncommonly detected in needle biopsies. Note the presence of lymphocytes, 
macrophages and eosinophils within the intima of the affected artery (large arrow), the 
endothelial hypertrophy in a nearby capillary (*).  The inset (40X) shows C4d positivity 
(brown staining) in a portal capillary (*) and sinusoids (small arrow). 
 
Figure 5: (A) The Acute-AMR (aAMR) score to predict antibody-mediated rejection was 
developed from 4 pathologists’ scores on the training cohort and validated on a 
separate cohort.  (B) The Odds Ratio demonstrates the aAMR model’s association with 
a diagnosis of acute AMR on the training and validation cohorts. (C) SPSS16 tree 
classification developed diagnostic categories on the training set that were 
subsequently validated. Sensitivity and specificity of 2 different cutoffs are presented for 
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the training and validation cohorts; the higher cutoff optimizes specificity, while the lower 
cutoff optimizes sensitivity.  
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Table 1: Patient characteristics of the training cohort from University of Pittsburgh 
Medical Center (UPMC) and the validation cohort from Edinburgh University and 
Baylor University Medical Center (BUMC) are seen. Medians with interquartile 
ranges are presented where appropriate. 
  UPMC* Edinburgh* BUMC** 
Number 26 10 27 
C4d positive 13; 50% 5; 50% 3; 11% 
Male Gender 46%  10%  59% 
Age 55 (42-59) 55.5 (50-59) 53 (38-57) 
Model for End-Stage Liver 
Disease 18 (14-23)  15.5 (11-16)  18 (14-24) 
Cold Ischemia Time 
(hours)  9.8(8.1-12.4) 9.9 (7.7-13.2)  9.3 (5.6-11.1) 
Hepatocellular Carcinoma 8%  30%  14% 
HCV RNA Positive 31%  10%  0% 
Recipient 
Race 
Caucasian 96%  100% 73% 
African-
American 4%  0% 10% 
Other 0%  0% 17% 
Donor 
Race 
Caucasian 69%  100% 62% 
African-
American 27%  0% 14% 
Other 4%  0% 24% 
Donor age 53 (41-74) 56 (49-67)  54 (39-61) 
Induction   0% 0%  24% 
Calcineurin^  100% 100%  81% 
Steroids^ 100%  100%  52% 
Sirolimus^ 0%  0%  26% 
Mycophenolate^ 38%  0%  44% 
 
*C4d positive cases of rejection within 21 days of transplant were matched by 
Banff grade to C4d negative cases of rejection. 
**All HCV RNA negative patients with steroid resistant rejection within 60 days of 
transplant from 1/1/00 to 5/31/09 who had a pre-transplant sample tested for 
donor-specific antibodies were stained for C4d.  
^ Immunosuppression at the time of rejection. 
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Table 2: Comparison of pre-transplant serological and C4d staining data for 
patients from (A) University of Pittsburgh Medical Center (UPMC); (B) Edinburgh 
University; and (C) Baylor University Medical Center (BUMC) (See Materials and 
Methods: case selection and study design). C4d staining was considered positive 
only when it was diffuse (>50% of portal tracts). 
(A) 
 UPMC 
Total Patients/biopsies 26 
C4d positive Positive by cytotoxic T-cell 
crossmatch 
5 
Negative by cytotoxic T-cell 
crossmatch 
8 
C4d negative Positive by cytotoxic T-cell 
crossmatch 
1 





  Edinburgh 
Total Patients/biopsies 10 
C4d positive None 0 
Positive by class I & II SAB 2 
Positive T-cell by flow 
cytometry crossmatch 1 
Positive by T-cell cytotoxic 
crossmatch 2 
C4d negative Negative by Single Antigen 
Beads 4 




  BUMC* 
Total Patients/biopsies 27 
C4d positive None 0 
Class I 1 
Class II 1 
Class I & II 1 
C4d negative None 24 
Class I 0 
Class II 0 
Class I & II 0 
 * Only cases with at least one individual donor-specific HLA Alloantibody with a 
MFI >5000 were considered positive.  
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Table 3: In the (A) University of Pittsburgh Medical Center (UPMC) training 
cohort and (B) Edinburgh University and Baylor University Medical Center 
(BUMC) validation cohort, the odds ratios for all 4 pathologists (blinded to C4d 
results) for the 9 variables with the highest positive or inverse correlations with 
C4d positive rejection are displayed. Kendell’s coefficient of concordance 
displays the inter-observer variability. 
 
(A) 
  Odds Ratio [CI] P-value 
Coefficient of 
Concordance 
Eosinophilic Central Venulitis 1.93 [1.25-2.96] 0.003 0.49 
Portal Vein Endothelial Cell 
Hypertrophy 1.89 [1.19, 2.99] 0.007 0.42 
Eosinophilic Portal Venulitis 2.48 [1.24-4.96] 0.01 0.30 
Central Venulitis Severity 2.26 [1.2-4.25] 0.02 0.33 
Lymphocytic Portal Inflammation 0.59 [0.34-1.03] 0.06 0.40 
Portal Eosinophilia 1.43 [0.92-2.21] 0.11 0.40 
Lymphocytic Venulitis 0.78 [0.49-1.24] 0.3 0.32 
Hepatocyte Ballooning 1.14 [0.76-1.72] 0.53 0.44 
Cholestasis 1.00 [0.71-1.42] 1 0.29 
 
(B) 
  Odds Ratio [CI] P-value 
Coefficient of 
Concordance 
Eosinophilic Central Venulitis 2.48 [1.37-4.49] 0.003 0.63 
Portal Vein Endothelial Cell 
Hypertrophy 
2.88 [1.83-4.55] <0.001 
0.62 
Eosinophilic Portal Venulitis 3.05 [1.96-4.69] <0.001 0.38 
Central Venulitis Severity 2.44 [1.47-4.06] <0.001 0.63 
Lymphocytic Portal Inflammation 1.33 [0.79-2.22] 0.3 0.58 
Portal Eosinophilia 4.37 [2.54-7.51] <0.001 0.61 
Lymphocytic Venulitis 1.65 [1.05-2.58] 0.03 0.42 
Hepatocyte Ballooning 2.00 [1.35-2.95} <0.001 0.63 
Cholestasis 2.09 [1.35-2.95] <0.001 0.65 
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Portal Vein Endothelial    +    Portal    +    Eosinophilic Central    
    Cell Hypertrophy          Eosinophilia                  Venulitis               
Lymphocytic Portal   +    Lymphocytic 
      Inflammation                Venulitis 
A)  Acute-AMR (aAMR) Score 
(B) 
(C) 
           
Number 






  >1.75 >1 
Training Sensitivity 38% (20/52) 67% (35/52) 
Specificity 94% (49/52) 81% (36/52) 
Validation Sensitivity 34% (11/31) 81% (26/32) 
Specificity 87% (102/116) 71% (82/116) 
OR P-value 
Training 2.86 <0.001 
Validation 2.49 <0.001 
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